CHENGDU, China, Sept. 30 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co. Inc. , a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced that it will present at the Roth China Conference, to be held October 12-14, 2009, at Fontainebleau Miami Beach, FL.
Mr. Stewart Lor, Director, is scheduled to present at 12:30 pm ET on Wednesday, October 14th, 2009 and participate in one-on-one meetings with conference attendees throughout the three-day event. The presentation will discuss the Company's diversified product portfolio, customer base addressable market, competitive landscape, and recent financial results. Mr. Lor will provide additional details on the $126 billion government sponsored healthcare reform plan and its potential benefits to the Company's long-term growth strategy.
Registration is by invitation and registration is mandatory. For more information on the conference, contact your Roth representative or visit http://www.roth.com .
About ROTH Capital Partners
ROTH is a full service investment banking firm dedicated to the small and micro-cap market. The firm is privately owned with current principals being majority owners. The core management team has been consistent for many years. Since the inception of the firm in 1984, ROTH has been a leader and innovator in the small and micro cap markets. Roth's exclusive focus has been, is, and will continue to offer a full spectrum of investment banking services, including raising capital, research coverage, trading and market making, merger and acquisition advisory services, and investor conferences.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 40 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts during the presentation are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
SOURCE Tianyin Pharmaceutical Co. Inc.
CONTACT: Allen Tang, Ph.D., MBA, Assistant to the CEO in China, +86-158-
2122-5642, or Allen.y.tang@gmail.com; or Mr. Matthew Hayden of HC
International, +1-561-245-5155, or matt.hayden@hcinternational.net, for TPI
Web site: http://www.tianyinpharma.com/
